
CLAIMS

1. A compound of Formula (I-b):



(I-b), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:

A is nitrogen-containing heterocyclyl, optionally substituted with one or more R^1;

B is nitrogen-containing heteroaryl, optionally substituted with one or more R^1;

L is -O-, -N(R^3)-, -N(R^3)C(O)-, or -C(O)N(R^3)-;

M and P are each independently C(R^2) or N; wherein both of M and P are not N;

X is N and Y is C(R^{5a}), wherein the bond between X and Y may be a single or double bond as valency permits;

each R^1 is independently hydrogen, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C_1-C_6 alkylene-aryl, C_1-C_6 alkenylene-aryl, C_1-C_6 alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –OR^A, –NR^BR^C, –$NR^BC(O)R^D$, –NO_2, –$C(O)NR^BR^C$, –$C(O)R^D$, –$C(O)OR^D$, –SR^E, or –$S(O)_xR^D$, wherein each alkyl, alkylene, alkenyl, alkenylene, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R^8; or

two R^1 groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R^8;

each R^2 is independently hydrogen, halo, cyano, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, or –OR^A;

each R^3 is independently hydrogen, C_1-C_6-alkyl, or C_1-C_6-haloalkyl;

R^{5a} is selected from hydrogen, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, halo, cyano, oxo, –OR^A, –NR^BR^C, –$C(O)R^D$, or –$C(O)OR^D$;

each R^7 is independently C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, halo, oxo, cyano, $NR^BC(O)R^D$, –$C(O)NR^BR^C$, –$C(O)R^D$, or –SR^E, wherein alkyl, alkenyl, alkynyl, heteroalkyl, and haloalkyl are optionally substituted with one or more R^9;

R^8 and R^9 are each independently C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, $–OR^A$, $–NR^BR^C$, $–NR^BC(O)R^D$, $–NO_2$, $–C(O)NR^BR^C$, $–C(O)R^D$, $–C(O)OR^D$, $–SR^E$, or $–S(O)_xR^D$, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R^{11};

each R^A is independently hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C_1-C_6 alkylene-aryl, C_1-C_6 alkylene-heteroaryl, $–C(O)R^D$, or $–S(O)_xR^D$;

each of R^B and R^C is independently hydrogen, C_1-C_6 alkyl, C_1-C_6-heteroalkyl, cycloalkyl, heterocyclyl, $–OR^A$; or

R^B and R^C together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R^{10};

each R^D and R^E is independently hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 heteroalkyl, C_1-C_6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C_1-C_6 alkylene-aryl, or C_1-C_6 alkylene-heteroaryl;

R^{10} is C_1-C_6-alkyl or halo;

each R^{11} is independently C_1-C_6-alkyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or $–OR^A$;


n is 0, 1, 2, 3, or 4; and

x is 0, 1, or 2.


2. The compound of claim 1, wherein A is a monocyclic or bicyclic heterocyclyl.










3. The compound of any one of the preceding claims, wherein A is monocyclic heterocyclyl.


4. The compound of any one of the preceding claims, wherein A is selected from








5. The compound of any one of the preceding claims, wherein A is selected from












,

,

,

,

,

,

,

,

,











, and

.





6. The compound of any one of the preceding claims, wherein A is selected from


,

,

,

, and

.

7. The compound of any one of the preceding claims, wherein B is selected from






,

,

,

,

,

,

, and

.

8. The compound of any one of the preceding claims, wherein B is selected from

,

,

,

,

,

,

,

,

, and

.

9. The compound of any one of the preceding claims, wherein B is selected from , , , and .


10. The compound of any one of the preceding claims, wherein L is -O- or -N(R^3)-.

11. The compound of any one of the preceding claims, wherein L is -N(R^3)-.

12. The compound of any one of the preceding claims, wherein  is selected from , , and .

13. The compound of any one of the preceding claims, wherein each of M and P is independently C(R^2).


14. The compound of any one of claims 1-13, wherein the compound is a compound of Formula (I-c):



(I-c),

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, R^2, R^{5c}, R^7, n, and subvariables thereof are as described in claim 1 and wherein m is 2.


15. The compound of any one of claims 1-13, wherein the compound is a compound of Formula (I-e):



(I-e),

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, R^2, R^{5a}, R^7, n, and subvariables thereof are as described in claim 1; and wherein m is 2.


16. The compound of any one of claims 1-13, wherein the compound is a compound of Formula (I-f):



(I-f),

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, X, Y, R^3, R^7, n, and subvariables thereof are as described in claim 1.


17. The compound of any one of claims 1-13, wherein the compound is a compound of Formula (I-g):



(I-g),

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, R^2, R^7, n, and subvariables thereof are as described in claim 1, R' is hydrogen, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-heteroalkyl, C_1-C_6-haloalkyl, cycloalkyl, –$C(O)R^D$, or –$C(O)OR^D$, and wherein m is 2.

18. The compound of any one of claims 1-13, wherein the compound is a compound of Formula (I-h):



(I-h),






or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:









A is 6-membered heterocyclyl, or heteroaryl, each of which is optionally substituted with one or more R^1;








B is 5-membered heteroaryl, each of which is optionally substituted with one or more R^1; and








L, R^{5a}, R^2, R^7, n, and subvariables thereof are as described in claim 1; and wherein m is 2.








19. The compound of any one of the preceding claims, wherein the compound is selected from:







125	
126	
127	
128	
129	







130	
133	
134	
135	
136	
161	
162	
171	








217	
236	
244	
245	
246	
247	
248	





249	
250	
256	
257	
258	
259	
260	

261	
262	
268	
269	
270	
271	
272	

283	
284	
285	
286	
287	
288	

289	
290	
291	
292	
293	
294	

295	
296	
297	
298	
299	
300	
301	

302	
303	
304	
305	

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

20. A pharmaceutical composition comprising a compound of any one of the preceding claims and a pharmaceutically acceptable excipient.

21. The compound of any one of claims 1-19, or the pharmaceutical composition of claim 20, wherein the compound:

(i) alters a target nucleic acid

(ii) binds to a target nucleic acid; and/or

(iii) stabilizes a target nucleic acid.

22. The compound of any one of claims 1-19, or the pharmaceutical composition of claim 20, wherein the compound:

(i) increases splicing at splice site on a target nucleic acid, by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR; or

(ii) decreases splicing at splice site on a target nucleic acid, by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR %.

23. An *in vitro* method of forming a complex comprising a component of a spliceosome, a nucleic acid , and a compound of Formula (I-b) according to any one of claims 1-19, comprising contacting the nucleic acid with a compound of Formula (I-b).

24. The *in vitro* method of claim 23, wherein the component of a spliceosome is recruited to the nucleic acid in the presence of the compound of Formula (I-b).

25. An *in vitro* method of altering the conformation of a nucleic acid comprising contacting the nucleic acid with a compound of Formula (I-b) according to any one of claims 1-19 or the pharmaceutical composition of claim 20.

26. The *in vitro* method of claim 25, wherein the altering comprises:
(i) forming a bulge in the nucleic acid;
(ii) stabilizing a bulge in the nucleic acid; and/or
(iii) reducing a bulge in the nucleic acid.

27. Use of a compound of Formula (I-b) according to any one of claims 1-19 or the pharmaceutical composition of claim 20 in the manufacture of a medicament for the treatment of a disease of disorder in a subject.

28. The use of claim 27, wherein the disease or disorder comprises a proliferative disease.

29. The use of claim 27, wherein the disease or disorder comprises a neurological disease or disorder, autoimmune disease or disorder, immunodeficiency disease or disorder, lysosomal storage disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, respiratory disease or disorder, renal disease or disorder, or infectious disease.

30. The use of claim 27, wherein the disease or disorder comprises neurological disease or disorder.

31. The use of claim 27, wherein the disease or disorder comprises Huntington's disease.

32. A compound of Formula (I-b) according to any one of claims 1-19 or the pharmaceutical composition of claim 20 for use in therapy.